Zobrazeno 1 - 10
of 10
pro vyhledávání: '"William Gwin"'
Autor:
Xiao Yang, Tao Wang, Michael A Morse, Takuya Osada, William Gwin, Herbert Kim Lyerly, Cong-Xiao Liu, Pankaj Agarwal, Hiroshi Nagata, Erika J Crosby, Pei Zhong, Shinya Abe, Yoshiyuki Inoue, Kensuke Kaneko, Chaitanya R Acharya, Joshua Snyder
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/f1a40627b3444ff2afb9da9c50ee6a96
Autor:
Zachary C. Hartman, H. Kim Lyerly, Michael A. Morse, Amy C. Hobeika, Takuya Osada, Joshua C. Snyder, Veronica Lubkov, Andre Rogatko, Sungjin Kim, Terry Hyslop, Gloria Broadwater, Holden T. Maecker, Serena Chang, Paul K. Marcom, Kimberly Blackwell, William Gwin, Erika J. Crosby
CYTOF Panel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb60f2e939b7f8d0e65a71033da6e52
https://doi.org/10.1158/1078-0432.22472850
https://doi.org/10.1158/1078-0432.22472850
Autor:
Zachary C. Hartman, H. Kim Lyerly, Michael A. Morse, Amy C. Hobeika, Takuya Osada, Joshua C. Snyder, Veronica Lubkov, Andre Rogatko, Sungjin Kim, Terry Hyslop, Gloria Broadwater, Holden T. Maecker, Serena Chang, Paul K. Marcom, Kimberly Blackwell, William Gwin, Erika J. Crosby
SPADE tree generated by CYTOF analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5f6960c13db7e818c40db0139b1ea7
https://doi.org/10.1158/1078-0432.22472856.v1
https://doi.org/10.1158/1078-0432.22472856.v1
Autor:
Zachary C. Hartman, H. Kim Lyerly, Michael A. Morse, Amy C. Hobeika, Takuya Osada, Joshua C. Snyder, Veronica Lubkov, Andre Rogatko, Sungjin Kim, Terry Hyslop, Gloria Broadwater, Holden T. Maecker, Serena Chang, Paul K. Marcom, Kimberly Blackwell, William Gwin, Erika J. Crosby
Purpose:Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T-cell infiltration of tumors include vaccines targeting established oncogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffe62ca5bb4291916b205066b819c00
https://doi.org/10.1158/1078-0432.c.6528351.v1
https://doi.org/10.1158/1078-0432.c.6528351.v1
Autor:
Hyo S Han, Mary Disis, Robert Wesolowski, Carla Fisher, Shipra Gandhi, Nancy Chan, William Gwin, Keerthi Gogineni, Rosemarie Mick, Christina Sierra Rodriguez, Deanna Hogue, Hien Liu, Ricardo Costa, Brian Czerniecki
Publikováno v:
Cancer Research. 82:OT1-16
Background: HER2-positive breast cancer patients are commonly treated with neoadjuvant therapy including HER2-targeted therapy. Patients who have residual invasive disease have less favorable outcomes with an increased risk of recurrent disease than
Autor:
Mary Disis, Ying Liu, Sasha Stanton, William Gwin, Andrew Coveler, John Liao, Jennifer Childs, Denise Cecil
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Shinya Abe, Hiroshi Nagata, Erika J Crosby, Yoshiyuki Inoue, Kensuke Kaneko, Cong-Xiao Liu, Xiao Yang, Tao Wang, Chaitanya R Acharya, Pankaj Agarwal, Joshua Snyder, William Gwin, Michael A Morse, Pei Zhong, Herbert Kim Lyerly, Takuya Osada
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundDespite multimodal adjuvant management with radiotherapy, chemotherapy and hormonal therapies, most surgically resected primary breast cancers relapse or metastasize. A potential solution to late and distant recurrence is to augment systemi
Autor:
Hope Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William Gwin, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Emily Ashley, Shengyan Hong, Minori Rosales, William J. Gradishar
Publikováno v:
Cancer Research. 82:PD8-01
Background: CTX + dual HER2-targeting monoclonal antibodies (mAb) remains a standard of care for treatment (Tx) of both HER2+ early-stage and MBC. However, when the SOPHIA trial was launched, limited Tx options existed after progression on T, pertuzu
Autor:
Erika J, Crosby, William, Gwin, Kimberly, Blackwell, Paul K, Marcom, Serena, Chang, Holden T, Maecker, Gloria, Broadwater, Terry, Hyslop, Sungjin, Kim, Andre, Rogatko, Veronica, Lubkov, Joshua C, Snyder, Takuya, Osada, Amy C, Hobeika, Michael A, Morse, H Kim, Lyerly, Zachary C, Hartman
Publikováno v:
Clin Cancer Res
BACKGROUND: Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T cell infiltration of tumors include vaccines targeting established onc
Autor:
William, Gwin, Richard F, Riedel
Publikováno v:
Oncology (Williston Park, N.Y.). 29(1)